Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia

Cancer Biology and Therapy

Volumn 14, Issue 10, 2013, Pages 916-921

  Guo, Wenjian ^a   Xing, Chao ^a   Dong, Aishu ^a   Lin, Xiaoji ^a   Lin, Ying ^a   Zhu, Baoling ^a   He, Muqing ^a   Yao, Rongxing ^a  

^a THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

CD3+CD56+ T lymphocyte; Cell's cytotoxicity; Cell's number; Primary acute leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; PERFORIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CD3+ CD56+ T LYMPHOCYTE; CD3+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; PERIPHERAL LYMPHOCYTE; PROTEIN EXPRESSION;

CD3+CD56+ T LYMPHOCYTE; CELL'S CYTOTOXICITY; CELL'S NUMBER; PRIMARY ACUTE LEUKEMIA;

ANTIGENS, CD3; ANTIGENS, CD56; CASE-CONTROL STUDIES; CYTOTOXICITY, IMMUNOLOGIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOCYTE COUNT; PERFORIN; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84885203873     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25938     Document Type: Article

References (22)

1. Mellman I, Coukos G, Dranoff G. Cancer immu-notherapy comes of age. Nature 2011; 480:480-9; PMID:22193102; http://dx.doi.org/10.1038/nature10673
2. Horowitz MM, Gale R P, Sondel PM, Goldman JM, Kersey J, Kolb HJ, Rimm AA, Ringdén O, Rozman C, Speck B, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75:555-62; PMID:2297567 (Pubitemid 20069191)
3. Görgün G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest 2005; 115:1797-805; PMID:15965501; http://dx.doi.org/10.1172/JCI24176 (Pubitemid 40979718)
4. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce CM, Gribben JG. E(mu)-TCL1 mice represent a model for immuno-therapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci USA 2009; 106:6250-5; PMID:19332800; http://dx.doi. org/10.1073/pnas.0901166106
5. Dustin ML, Cooper JA. The immunological synapse and the actin cytoskeleton: molecular hardware for T cell signaling. Nat Immunol 2000; 1:23-9; PMID:10881170; http://dx.doi.org/10.1038/76877
6. Ramsay AG, Johnson AJ, Lee AM, Gorgün G, Le Dieu R, Blum W, Byrd JC, Gribben JG. Chronic lympho-cytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immu-nomodulating drug. J Clin Invest 2008; 118:2427-37; PMID:18551193 (Pubitemid 351949771)
7. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG. NKT cells: facts, functions and fallacies. Immunol Today 2000; 21:573-83; PMID:11094262; http://dx.doi.org/10.1016/S0167-5699(00)01735-7
8. Joyce S. CD1d and natural T cells: how their properties jump-start the immune system. Cell Mol Life Sci 2001; 58:442-69; PMID:11315191; http://dx.doi. org/10.1007/PL00000869 (Pubitemid 32231978)
9. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000; 164:1148-52; PMID:10640724 (Pubitemid 30067223)
10. Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, Hiraide H, Sekine I. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001; 103:281-90; PMID:11454057; http://dx.doi.org/10.1046/j.1365- 2567.2001.01248.x (Pubitemid 32626177)
11. Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153:1687-96; PMID:7519209 (Pubitemid 24251113)
12. Schmidt-Wolf GD, Negrin RS, Schmidt-Wolf IG. Activated T cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 1997; 74:51-6; PMID:9063373; http://dx.doi.org/10.1007/s002770050257 (Pubitemid 27095476)
13. Hoyle C, Bangs CD, Chang P, Kamel O, Mehta B, Negrin RS. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998; 92:3318-27; PMID:9787169 (Pubitemid 28492340)
14. Gritzapis AD, Dimitroulopoulos D, Paraskevas E, Baxevanis CN, Papamichail M. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich superna-tants. Cancer Immunol Immunother 2002; 51:440-8; PMID:12202905 (Pubitemid 35013651)
15. Guven H, Gilljam M, Chambers BJ, Ljunggren HG, Christensson B, Kimby E, Dilber MS. Expansion of natural killer (NK) and natural killer-like T (NKT)-cell populations derived from patients with B-chronic lymphocytic leukemia (B-CLL): a potential source for cellular immunotherapy. Leukemia 2003; 17:1973-80; PMID:14513047; http://dx.doi.org/10.1038/sj.leu.2403083 (Pubitemid 37322127)
16. Le Dieu R, Taussig DC, Ramsay AG, Mitter R, Miraki-Moud F, Fatah R, Lee AM, Lister TA, Gribben JG. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood 2009; 114:3909-16; PMID:19710498; http://dx.doi.org/10.1182/blood-2009-02-206946
17. Okada H, Nagamura-Inoue T, Mori Y, Takahashi TA. Expansion of Valpha24(+)Vbeta11(+) NKT cells from cord blood mononuclear cells using IL-15, IL-7 and Flt3-L depends on monocytes. Eur J Immunol 2006; 36:236-44; PMID:16380959; http://dx.doi. org/10.1002/eji.200526085 (Pubitemid 43116410)
18. Chamoto K, Takeshima T, Kosaka A, Tsuji T, Matsuzaki J, Togashi Y, Ikeda H, Nishimura T. NKT cells act as regulatory cells rather than killer cells during activation of NK cell-mediated cytotoxicity by alpha-galactosylceramide in vivo. Immunol Lett 2004; 95:5-11; PMID:15325792; http://dx.doi.org/10.1016/j. imlet.2004.04.012 (Pubitemid 39119894)
19. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. Prevention of autoimmunity by targeting a distinct, noninvariant CD1d-reactive T cell population reactive to sulfatide. J Exp Med 2004; 199:947-57; PMID:15051763; http://dx.doi.org/10.1084/jem.20031389 (Pubitemid 38481086)
20. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med 2005; 202:1623-6; PMID:16365145; http://dx.doi.org/10.1084/ jem.20051600 (Pubitemid 41815867)
21. Gütgemann S, Frank S, Strehl J, Schmidt-Wolf IG. Cytokine-induced killer cells are type II natural killer T cells. Ger Med Sci 2007; 5:Doc07; PMID:19675715
22. Rumi C, Rutella S, Teofili L, Etuk B, Ortu La Barbera E, Micciulli G, Voso MT, Leone G. RhG-CSF-mobilized CD34+ peripheral blood progenitors are myeloperoxidase-negative and noncycling irrespective of CD33 or CD13 coexpression. Exp Hematol 1997; 25:246-51; PMID:9091301 (Pubitemid 27130302)